Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.

T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.

AI Tool May Predict Response, Resistance in Advanced RCC

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Olanzapine May Reduce Nausea, Vomiting From Radiation

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing 

®. Gina joined the company in 2015 and has held various positions on 

Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

Sabrina Serani is a senior editor for Targeted Oncology.

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer 

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

View

Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma

MonumenTAL-1: Long Term Follow up Efficacy

Larysa Sanchez, MD; and Samantha Shenoy, MSN, NP, discuss the management of adverse events with bispecific antibodies like GPRC5D and talquetamab while providing guidance on optimizing treatment outcomes and supportive care, as well as offering advice for managing toxicities and future perspectives on relapsed/refractory multiple myeloma.

Medical experts  give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies

Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.

Experts give an overview of safety data from the MonumenTAL-1 study.

MonumenTAL-1: Safety and AEs

Experts address the unique challenges in managing adverse events associated with GPRC5D therapies compared to other cancer treatments, while Samantha will discuss strategies for preparing and educating patients undergoing GPRC5D therapy.

Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS 

Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.

Managing toxicities of BCMA_targeting Bispecfics

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

Management of Oral Toxcities associated with GPRC5D Bispecifics Nail

Experts discuss prophylactic measures for managing potential adverse events associated with talquetamab and other bispecifics, while all faculty will offer advice for health care providers involved in the care of patients receiving talquetamab.

Prophylactic Strategies and Advice for Managing AEs in  Bispecific Therapies 

Experts provide advice to patients and caregivers on managing oral and skin toxicities.

Management of Skin and Nail AEs: Advice to Patients and Caregivers

Experts provide advice for patients and caregivers with relapsed/refractory multiple myeloma considering talquetamab or another bispecific, while all faculty will discuss unmet needs and future perspectives in the treatment of relapsed/refractory multiple myeloma.

Unmet Needs and Future Perspectives on the treatment of R/R MM 

MonumenTAL-1: Long Term Follow up Efficacy

EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

EP: 2.MonumenTAL-1: Long Term Follow up Efficacy

EP: 3.MonumenTAL-1: Safety and AEs

EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

EP: 6.Managing toxicities of BCMA_targeting Bispecfics

EP: 7.Management of Oral Toxcities associated with GPRC5D Bispecifics Nail

EP: 8.Prophylactic Strategies and Advice for Managing AEs in Bispecific Therapies

EP: 9.Management of Skin and Nail AEs: Advice to Patients and Caregivers

EP: 10.Unmet Needs and Future Perspectives on the treatment of R/R MM

Newsletter

Latest Conference Coverage